Anthem Biosciences bets ₹1,200 cr on GLP-1 plant expansion
Management is doubling custom synthesis capacity to chase Indian GLP-1 demand after posting record quarterly revenue of ₹611 cr.
What's new
- Quarterly revenue hit a record ₹611 cr.
- Capex of ₹1,200 cr will double custom synthesis capacity by March 2028.
- GLP-1 products target the Indian market within 6-8 months.
Why it matters
The company is tying its future to the GLP-1 wave by adding substantial capacity. With 10 Phase 3 molecules now in its pipeline, the firm is shifting from a simple service provider to a late-stage manufacturing partner.
What we're watching
- Commercialization timeline for the GLP-1 active ingredient.
- Formulator approval status for new products.
- Actual EBITDA conversion as capacity expansion scales.
The full read
Anthem Biosciences just posted record quarterly revenue of ₹611 crore. It is not slowing down.
Management committed ₹1,200 crore to expand its Unit 4 facility, which aims to double custom synthesis capacity by March 2028. The strategy hinges on the Indian GLP-1 market, where the company expects to launch its active ingredient within the next 6-8 months, pending necessary formulator approvals. Beyond this immediate push, the pipeline has reached 10 Phase 3 molecules. While management held back on explicit FY27 guidance, they are targeting long-term growth of 20% across key profit and revenue metrics. Anthem is moving fast; the next test is whether those regulatory approvals arrive on the expected 6-8 month schedule. With a major capex cycle underway, the company has clearly pivoted toward scaling its late-stage pharmaceutical manufacturing footprint to capture share in the high-demand, high-complexity drug market.